



Metabolix Appoints Barbara H. Wells to Board of Directors

Agriculture and Biotechnology Industry Veteran to Help Guide Company's Growth in Bioplastics and Chemicals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today announced that Barbara H. Wells, Ph.D., has joined its board of directors, effective June 6, 2011. Dr. Wells brings 26 years of experience in the agriculture and biotechnology industries to help Metabolix grow its renewable bioplastics and chemicals businesses.

“Barbara also brings a unique international perspective to us through her years of living and working in South America, which will help the company shape our international strategy. We are looking forward to her contributions.”

Dr. Wells is currently the president and chief executive officer of [ArborGen](#), which she joined in 2002. Prior to ArborGen, she was the vice president in charge of Latin American growth initiatives and investments for Emergent Genetics, Inc., an agricultural investment firm. Dr. Wells also spent 18 years at Monsanto where her roles included serving as co-managing director of Monsanto Brazil and leader of the Roundup Ready soybean team. Throughout her career, she has developed international commercial and technical experience in agriculture, biotechnology and forestry.

“We are very pleased that Barbara Wells will be joining our board. Her broad experience and insight into biotechnology and agriculture will be exceptionally valuable to Metabolix as the company grows its business in these markets,” said Rick Eno, president and CEO of Metabolix. “Barbara also brings a unique international perspective to us through her years of living and working in South America, which will help the company shape our international strategy. We are looking forward to her contributions.”

Dr. Wells received her Ph.D. in agronomy from Oregon State University. She earned her M.S. degree in plant pathology and B.S. degree with honors in horticulture from the University of Arizona. She served as the president of the board of directors of Producers S.A. in Argentina, and the boards of Monsanto Brazil, Monsoy and Maeda Delta Pine Monsanto JV. She currently serves on the executive committee of the board of directors of the Biotechnology Industry Organization and is vice chairman of the Food and Agricultural Sector board. She is an advisory committee member of the Joint BioEnergy Institute and has previously served as a board member for the Forest Biotechnology Institute.

About Metabolix

Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel™, a family of high-performance bioplastics, which are biobased and biodegradable alternatives to many petroleum-based plastics, through Telles, a joint venture between Metabolix and Archer Daniels Midland Company. Metabolix is also developing biosourced industrial chemicals and a proprietary platform technology for co-producing plastics, chemicals and energy, from crops such as switchgrass, oilseeds and sugarcane. For more information, please visit <http://www.metabolix.com>. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for Metabolix research and development programs, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that

could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

Contacts

Media:

Schwartz Communications

Keith Giannini or Jen Barlow, 781-684-0770

metabolix@schwartzcomm.com

or

Investors:

ICR

James Palczynski, 203-682-8229

james.palczynski@icrinc.com